Bayer to commercialize TRK inhibitor as Roche creates competition
Bayer exercises its option to obtain exclusive licensing rights for the global development and commercialization of Loxo Oncology’s solid tumor drugs.
Archives for February 21, 2019
SCOPE 2019
Sites challenged with fragmented processes that ‘drain resources’
Clinical trial sites are challenged by fragmented financial processes, according to a new study by the Society of Clinical Research sites and Greenphire released this week at SCOPE 2019.
Merck in $300m Immune Design boost for Keytruda
Announced today, the deal sees Merck pay $5.85 per share to acquire Immune Design and its portfolio of late-stage immunotherapies.
SCOPE 2019
Solving pharma’s ‘big text’ problem with NLP
There are about 27m articles in PubMed and 280,000 studies on ClinicalTrials.gov – so how does the industry begin to make sense of all this data?
Lonza uses its ‘global footprint’ in hematopoietic commercialization agreement
Lonza enters private label partnership to manufacture and globally commercialize AllCell’s hematopoietic primary cells to provide greater access to researchers.
‘Just a few mouse clicks’: TriNetX offers RWD analytics
Global health research network, TriNetX, has added an analytic self-service offering for simplified analysis of real-world data.
PPD signs exclusive agreement with China-based AI company
PPD’s agreement with China-based Happy Life Tech focuses on site selection, patient recruitment, and real-world evidence generation for customers globally.